PAVM Jun 2024 2.500 call
- PR Newswire
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute-Designated Comprehensive Can
- PR Newswire
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 International Association of Fire Fighte
- GuruFocus.com
PAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...
Explore PAVmed Inc's strategic initiatives and financial performance, including a significant partnership with Ohio State's James Cancer Hospital and a robust Series B financing round.
